Clovis Oncology Announces First Patient Enrolled in the Phase II Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers

Clovis Oncology, Inc. announcedtreatment of the first patient in the Phase II portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis’ investigational angiogenesis inhibitor, including VEGFR1-3, and Opdivo®, Bristol Myers Squibb’s PD-1 inhibitor, for the treatment of gynecologic cancers.
[Clovis Oncology, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Everest Medicines Announces First Patient Dosed in a Phase 1b/2 Study of FGF401 in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors

Everest Medicines has announced that the first patient has been dosed in a Phase Ib/II study evaluating FGF401 in combination with PD-1 inhibitor, pembrolizumab, in patients with advanced solid tumors, such as hepatocellular carcinoma.
[Everest Medicines]
Press Release
Bookmark

No account yet? Register

0
Share

Dihydroxystilbenes Prevent Azoxymethane/Dextran Sulfate Sodium-Induced Colon Cancer by Inhibiting Colon Cytokines, a Chemokine, and Programmed Cell Death-1 in C57BL/6J Mice

The three dihydroxystilbenes in this study inhibited colon carcinogenesis and tumor growth as well as increases in colon IL-1β, IL-6, MCP-1, and PD-1 levels in AOM/DDS-treated mice in vivo. The three dihydroxystilbenes also suppressed COX-2 expression in colon tumors in vivo and inhibited PD-1 elevations in M2-THP-1 macrophages in vitro.
[European Journal of Pharmacology]
Abstract
Bookmark

No account yet? Register

0
Share

Reversal of Pre-Existing NGFR-Driven Tumor and Immune Therapy Resistance

Researchers chronically exposed patient-derived melanoma cell lines to differentiation antigen-specific cytotoxic T cells and observed strong enrichment of a pre-existing NGFRhi population.
[Nature Communications]
Boshuizen, J., Vredevoogd, D. W., Krijgsman, O., Ligtenberg, M. A., Blankenstein, S., de Bruijn, B., Frederick, D. T., Kenski, J. C. N., Parren, M., Brüggemann, M., Madu, M. F., Rozeman, E. A., Song, J.-Y., Horlings, H. M., Blank, C. U., van Akkooi, A. C. J., Flaherty, K. T., Boland, G. M., & Peeper, D. S. (2020). Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. Nature Communications, 11(1), 3946. https://doi.org/10.1038/s41467-020-17739-8 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC)

Merck announced that the FDA has accepted two new supplemental Biologics License Applications for KEYTRUDA, Merck’s anti-PD-1 therapy.
[Merck]
Press Release
Bookmark

No account yet? Register

0
Share

A Nanoscale Metal Organic Frameworks-Based Vaccine Synergises with PD-1 Blockade to Potentiate Anti-Tumor Immunity

Scientists designed an ultrafast, low-temperature, and universal self-assembly route to integrate immunology-associated large molecules into metal-organic-framework-gated mesoporous silica as cancer vaccines.
[Nature Communications]
Li, X., Wang, X., Ito, A., & Tsuji, N. M. (2020). A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity. Nature Communications, 11(1), 3858. https://doi.org/10.1038/s41467-020-17637-z Cite
Full Article
Bookmark

No account yet? Register

0
Share

Immune Checkpoint Inhibitor Induces Cardiac Injury through Polarizing Macrophages via Modulating microRNA-34a/Kruppel-Like Factor 4 Signaling

Scientists investigated the roles of programmed death-1 inhibitor, one of widespread used immune checkpoint inhibitors, in the development of murine cardiac injury.
[Cell Death & Disease]
Xia, W., Zou, C., Chen, H., Xie, C., & Hou, M. (2020). Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a/Kruppel-like factor 4 signaling. Cell Death & Disease, 11(7), 1–15. https://doi.org/10.1038/s41419-020-02778-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Transcriptome Profiling Identifies TIGIT as a Marker of T Cell Exhaustion in Liver Cancer

Investigators performed for the first time a comprehensive mRNA profiling of CD8 T cells in a murine model of autochthonous liver cancer by comparing the transcriptome of naive, functional effector and exhausted, tumor‐specific CD8 T cells.
[Hepatology]
Ostroumov, D., Duong, S., Wingerath, J., Woller, N., Manns, M. P., Timrott, K., Kleine, M., Ramackers, W., Roessler, S., Nahnsen, S., Czemmel, S., Dittrich‐Breiholz, O., Eggert, T., Kühnel, F., & Wirth, T. C. (n.d.). Transcriptome profiling identifies TIGIT as a marker of T cell exhaustion in liver cancer. Hepatology, n/a(n/a). https://doi.org/10.1002/hep.31466 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Radiogenomics for Predicting p53 Status, PD-L1 Expression, and Prognosis with Machine Learning in Pancreatic Cancer

107 patients diagnosed with pancreatic ductal adenocarcinoma were retrospectively examined. The relationship between p53 mutations as well as PD-L1 abnormal expression and clinicopathological factors was investigated using immunohistochemistry.
[British Journal of Cancer]
Iwatate, Y., Hoshino, I., Yokota, H., Ishige, F., Itami, M., Mori, Y., Chiba, S., Arimitsu, H., Yanagibashi, H., Nagase, H., & Takayama, W. (2020). Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer. British Journal of Cancer, 1–9. https://doi.org/10.1038/s41416-020-0997-1 Cite
Abstract
Bookmark

No account yet? Register

0
Share

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (Pembrolizumab) for Second-Line Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Merck announced that the FDA has accepted and granted priority review for a new supplemental Biologics License Application for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
[Merck & Co., Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

PD-L1 Promotes Tumor Growth and Progression by Activating WIP and β-Catenin Signaling Pathways and Predicts Poor Prognosis in Lung Cancer

Scientists showed that PD-L1 regulated lung cancer growth and progression by targeting the WIP and β-catenin signaling. Overexpression of PD-L1 promoted tumor cell growth, migration and invasion in lung cancer cells, whereas PD-L1 knockdown had the opposite effects.
[Cell Death & Disease]
Full Article
Bookmark

No account yet? Register

0
Share
Share